8-K filing — Emergent BioSolutions Inc. (EBS)
Filed: 2026-09-14 AccNo: 0001367644-26-000091 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Novavax Shorts on Edge as Russia Plague Fears Spread
Unconfirmed plague fears sent Novavax up 24% in a potential short squeeze, lifting vaccine stocks despite no clear link to its products.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider
The global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory.
Reported Earlier, Moderna To Replace Warner Bros. Discovery In Nasdaq-100 Index Before Market Open On October 9, 2026
Moderna Stock Is Trending: What's Going On?
Moderna Inc (NASDAQ:MRNA) shares are trending Thursday as the stock continues working through volatility following a bearish Citi downgrade earlier this week.
Novavax, Nvidia, MercadoLibre, Nu Holdings and PTC: Why These 5 Stocks Are on Investors' Radars Today
NVAX, NVDA, MELI, NU, PTC were among the stocks seen trending on Monday, Oct. 5, 2026.